

ML System

Uncertainty persists

We have once again lowered our valuation for ML System, this time by 52.3%, after cutting our EBITDA estimates by 40.2%, 37.2% and 29.4% for 2025, 2026 and 2027 respectively to reflect the persistent macroeconomic slowdown in the PV industry. The company is struggling to stay afloat and is expected to have several rounds of negotiations with the financing parties (BNP Paribas, Millennium Leasing, ARP, BGK) as well as state-owned agency KUKE, which may involve (and guarantee) part of the working capital proceeds required to relaunch production and execute contracts from the current backlog. The latter stands at PLN 231m, of which we believe at least PLN 140m needs to be realized in 2025. ML System lacks around PLN 40-60m in working capital needs to execute this minimal value of contracts slated for 2025. Another source of financing could be the disposal of real estate in the months ahead. We perceive this process as a kind of fire sale. The company has already lowered the salaries for workers with the aim of bringing rapid savings, but this carries the risk of key personnel leaving the firm. We lower our FV to PLN 15.03, down 52.3% from PLN 31.45 previously. We maintain our SELL recommendation.

Another non-binding term sheet signed: ML System has signed another non-binding Term Sheet agreement, this time with Golen Energy Technology. The latter will provide access to energy storage technologies, including the connection and management of storage facilities and energy management systems, while ML System will provide distribution channels, production infrastructure and an energy management system dedicated to PV and BIPV solutions, so that the product components manufactured in the EU will constitute at least 60% of the product value. The parties declared their willingness to establish a special purpose vehicle within four months from the date of signing the Term Sheet and to start production by end-2025. According to ML System, revenues from this source will amount to at least EUR 20m in 2026. We err on the side of caution and until this agreement transforms into a binding one we do not factor it into our forecast.

Standstill agreement necessary: There is still uncertainty regarding maintaining liquidity at ML System. The company assumes its creditors will refrain from actions aimed at collecting receivables and that the bank creditors will undertake terms to continue providing ML System with working capital financing. The intention of the parties is to immediately sign a cooperation agreement, i.e. a standstill agreement, to create a formal framework for the relations of ML System and its creditors during the transitional period needed to agree on the principles of further cooperation, implement remedial actions and ensure the stabilization of financing at ML System. The negotiated terms of the cooperation agreement provide that the initial period of validity will end on 31 May 2025, with the possibility of creditors expressing their consent to extend the period of validity; ML System assumes the period of such an extension would not exceed 12 months.

Figure 1. ML System financials (PLN m)

	2022	2023	2024	2025E	2026E	2027E
Revenue	281.7	189.3	162.3	174.7	265.2	364.4
EBIT	7.1	-9.1	-32.4	-7.6	-8.4	-0.1
EBITDA	36.5	18.2	-5.5	23.9	30.1	44.0
Net profit	0.2	-15.4	-40.8	-13.3	-13.9	-4.4
EPS	0.0	-2.2	-5.5	-1.8	-1.9	-0.6
DPS	0.0	0.0	0.0	0.0	0.0	0.0
P/E (x)	519.3	-7.8	-3.1	-9.6	-9.1	-29.0
EV/EBITDA (x)	5.6	13.7	-46.3	12.9	8.9	5.3

Source: Company, IPOPEMA Research

Technology

ML System

SELL

FV PLN 15.03

12.7% downside

Price as of 19 May 2025 PLN 17.22

Recommendation maintained



Share data

Number of shares (m)	7.4
Market cap (EUR m)	29.7
12M avg daily volume (k)	32.5
12M avg daily turnover (EUR m)	0.2
12M high/low (PLN)	55.9/12.8
WIG weight (%)	0.01
Reuters	MLSP.WA
Bloomberg	MLS PW

Total performance

1M	+42.0%
3M	+22.0%
12M	-59.9%

Shareholders

Dawid Cycoń	27.33%
Edyta Stanek	27.10%
NN OFE	5.89%

Analysts

Robert Maj
 robert.maj@ipopema.pl
 + 48 22 236 92 90

ML SYSTEM

SELL

FV PLN 15.03

Mkt Cap EUR 29.7m

Upside/downside -12.7%

Valuation multiples	2022	2023	2024	2025E	2026E
P/E (x)	519.3	-7.8	-3.1	-9.6	-9.1
EV/EBITDA (x)	5.6	13.7	-46.3	12.9	8.9
EV/Sales (x)	0.72	1.31	1.57	1.77	1.01
P/BV (x)	0.76	0.61	0.87	0.95	1.07
FCF yield (%)	-40%	na	-2%	-32%	32%
DY (%)	0%	0%	0%	0%	0%

Per share	2022	2023	2024	2025E	2026E
No. of shares (m units)	6.5	7.0	7.4	7.4	7.4
EPS (PLN)	0.03	-2.20	-5.53	-1.80	-1.88
BVPS (PLN)	22.58	28.36	19.84	18.04	16.16
FCFPS (PLN)	-6.97	-25.26	-0.40	-5.50	5.54
DPS (PLN)	0.00	0.00	0.00	0.00	0.00

Change y/y (%)	2022	2023	2024E	2025E	2026E
Revenues	49.2%	-32.8%	-14.3%	7.7%	51.8%
EBITDA	49.8%	-50.2%	-130.3%	-533.2%	26.3%
EBIT	60.8%	-228%	258%	-77%	11%
Pre-tax	-72.0%	na	182.6%	-64.6%	4.6%
Net profit	-87.7%	na	165.8%	-67.4%	4.6%

Leverage and return	2022	2023	2024	2025E	2026E
Gross margin (%)	13.1%	10.4%	9.1%	25.3%	26.0%
EBITDA margin (%)	13.0%	9.6%	-3.4%	13.6%	11.4%
EBIT margin (%)	2.5%	-4.8%	-20.0%	-4.3%	-3.2%
Net margin (%)	0.1%	-8.1%	-25.1%	-7.6%	-5.2%
Net debt / EBITDA (x)	2.51	7.05	-23.20	7.60	4.66
Net debt / Equity (x)	0.63	0.65	0.87	1.36	1.18
Leverage Ratio (x)	0.43	0.50	0.62	0.76	0.85
ROE (%)	0.1%	-8.9%	-23.7%	-9.5%	-11.0%
ROA (%)	0.3%	-17.8%	-38.5%	-12.6%	-12.9%
ROIC (%)	0.1%	-4.7%	-14.9%	-4.2%	-5.4%

Assumptions	2022	2023	2024	2025E	2026E
Sales (PLN m)	281.7	193.3	162.3	174.7	265.2
Quantum tiles/facades	0.0	0.0	0.0	0.0	41.2
PV	245.6	143.8	107.3	125.0	112.5
R&D	0.0	0.2	0.1	0.4	0.4
Unallocated	0.6	1.9	1.2	0.3	0.3
Quantum + 2D Glass	35.5	47.3	53.8	49.0	110.7
Active Glass	0.0	0.0	0.0	0.0	20.4
Poland GDP (%)	5.3%	0.2%	2.9%	4.3%	4.0%
Poland CPI (%)	14.3%	11.6%	3.7%	3.8%	3.0%
Constr. activity(%)	1.9%	1.9%	2.9%	2.7%	2.7%
USD PLN (avg)	4.46	4.20	3.97	3.92	3.86
EURPLN (avg)	4.68	4.54	4.31	4.23	4.25

P&L (PLN m)	2022	2023	2024	2025E	2026E	2027E
Revenues	281.7	189.3	162.3	174.7	265.2	364.4
Quantum tiles/facades	0.0	0.0	0.0	0.0	41.2	127.3
PV	245.6	143.8	107.3	125.0	112.5	101.3
R&D	0.0	0.2	0.1	0.4	0.4	0.4
Unallocated	0.6	1.9	1.2	0.3	0.3	0.3
Quantum + 2D Glass	35.5	47.3	53.8	49.0	110.7	135.1
Active Glass	0.0	0.0	0.0	0.0	20.4	42.1
Costs	-244.6	-169.5	-147.5	-130.4	-196.4	-250.1
SG&A	-30.6	-35.1	-49.5	-53.2	-80.9	-111.1
EBIT	7.1	-9.1	-32.4	-7.6	-8.4	-0.1
EBITDA	36.5	18.2	-5.5	23.9	30.1	44.0
Financial income (cost) net	-6.2	-5.7	-9.2	-7.2	-7.0	-4.8
Pre-tax	0.9	-14.7	-41.7	-14.8	-15.4	-4.9
Tax	-0.7	-0.6	0.9	1.5	1.5	0.5
Net profit	0.2	-15.4	-40.8	-13.3	-13.9	-4.4

BALANCE SHEET (PLN m)	2022	2023	2024	2025E	2026E	2027E
Non-current assets	256.4	433.1	414.9	429.7	432.5	435.6
Intangible assets	17.0	25.1	30.5	31.5	31.6	31.6
PP&E	217.5	384.1	350.7	364.3	366.1	368.2
Receivables	0.8	1.0	1.2	1.3	2.0	2.7
Current assets	174.8	145.6	81.5	83.0	124.9	167.4
Inventories	66.5	44.1	28.4	25.0	37.7	48.0
Trade receivables	69.0	71.4	40.3	38.3	58.1	79.9
Cash and equivalents	27.1	20.7	6.0	8.7	13.3	18.2
Other current assets	12.3	9.4	6.8	10.9	15.9	21.3
Total assets	431.2	578.7	496.4	512.7	557.4	603.0
Equity	146.4	197.9	146.5	133.2	119.3	115.0
Minorities	0.0	0.0	0.0	0.0	0.0	0.0
Non-current liabilities	133.8	228.8	213.6	195.7	267.6	326.6
Loans and leasing	46.7	73.5	69.6	67.7	74.9	80.7
Other non-current liabilities	87.1	155.3	144.1	128.0	192.7	245.9
Current liabilities	151.0	151.9	136.3	183.8	170.6	161.5
Trade payables	65.3	70.5	67.9	57.2	86.1	109.6
Loans and leasing	72.0	75.3	64.1	122.3	78.8	44.6
Other current liabilities	13.6	6.2	4.3	4.3	5.8	7.2
Equity & liabilities	431.2	578.7	496.4	512.7	557.4	603.0
Inventories turnover (days)	99.2	94.9	70.3	70.0	70.0	70.0
Receivable turnover (days)	89.4	137.7	90.7	80.0	80.0	80.0
Net debt (PLN m)	91.7	128.1	127.7	181.3	140.4	107.1

CASH FLOW (PLN m)	2022	2023	2024	2025E	2026E	2027E
Operating cash flow	10.3	6.2	37.6	2.4	88.8	84.8
Net income	0.2	-15.4	-40.8	-13.3	-13.9	-4.4
D&A	29.4	20.8	26.6	31.4	38.5	44.1
Change in WC	-24.9	-22.6	16.9	-9.4	-8.5	-13.9
Other	5.6	23.3	34.9	-6.3	72.7	59.1
Investment cash flow	-45.9	-171.6	-10.1	-31.3	-38.7	-44.4
CAPEX	-45.9	-171.6	72.3	-31.3	-38.7	-44.4
Other	0.0	0.0	-82.4	0.0	0.0	0.0
Financial cash flow	37.8	159.1	-42.2	31.6	-45.7	-35.5
Change in equity	0.0	56.2	0.0	0.0	0.0	0.1
Change in debt	27.8	31.8	-20.1	56.5	-36.4	-28.2
Lease payments	-3.5	-3.4	-20.0	-1.7	-1.8	-1.9
Interest	-6.1	-7.4	-10.4	-10.0	-7.5	-5.5
Other	19.7	82.0	8.4	-13.1	0.0	0.0
Change in cash	2.3	-6.3	-14.7	2.8	4.5	5.0
Cash as of eop	27.1	20.7	6.0	8.7	13.3	18.2

Source: Company data, IPOPEMA Research

CONTENTS

Valuation..... 4

 Relative valuation 5

 Changes in forecast..... 6

 4Q24 results overview 6

 1Q25 results preview 7

Risks to fair value 8

Financials..... 9

Valuation

Our valuation approach for construction companies uses two methods: the discounted cash flow (DCF) and the dividend discount model (DDM). We calculate our Fair Value for ML System by taking the average of the two results. The two methods are aligned, as they are both based on the same financial model. The model assumes cashflow projections over a 10-year period for the firm based on our forecasts for the photovoltaic and construction markets, and GDP in Poland as well as other parameters including volume growth, product mix changes, changes in the financing model, efficiency gains, production cost increases, capital expenditures and working capital needs. Our dividend projections are a derivative of the earnings forecasts in our financial model. Payout levels are determined by corporate policy in the short term (10%) and then drift towards a target payout ratio of 80% in the long-term. The DDM is also a useful tool for understanding P/E multiples $[P/E = (D/E)/(k-g)]$, with differences explained by a combination of earnings growth and dividend payout. Both our DCF and DDM models have terminal values with a growth rate of 2%.

Our assumptions for cost of equity were established by using a fixed risk-free rate of 5.5% and adding a 5.5% equity risk premium each year. We also consistently use a beta of one (1) so as not to distort the WACC and the comparability of our valuations.

Figure 2. DCF Valuation

PLN m	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	Terminal Year
Revenues	162.3	174.7	265.2	364.4	440.8	521.4	560.0	576.8	594.1	611.9	611.9
EBIT	-7.6	-8.4	-0.1	32.8	53.3	60.8	61.5	56.2	56.5	56.8	56.8
Tax on EBIT	-0.2	-0.8	0.0	3.3	10.1	11.6	11.7	10.7	10.7	10.8	10.8
NOPLAT	-7.4	-7.6	-0.1	29.5	43.1	49.3	49.8	45.5	45.8	46.0	46.0
Depreciation	31.4	38.5	44.1	41.5	44.2	47.2	50.4	53.7	57.3	61.2	61.2
Capital expenditures	-31.3	-38.7	-44.4	-41.6	-44.4	-47.4	-50.6	-54.0	-57.6	-61.5	-61.5
Change in working capital	-9.4	-8.5	-13.9	-13.6	-13.0	-5.7	-1.8	-0.4	-1.9	8.8	8.8
Leasing payments	-1.7	-1.8	-1.9	-2.0	-2.1	-2.2	-2.3	-2.3	-2.4	-2.6	-2.6
Free cash flow	-18.4	-18.0	-16.2	13.8	27.9	41.2	45.5	42.5	41.2	51.8	51.8
Risk-free rate	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%
Equity risk premium	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%
Beta	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Cost of equity	11.00%	11.00%	11.00%	11.00%	11.00%	11.00%	11.00%	11.00%	11.00%	11.00%	11.00%
Cost of debt (pre-tax)	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%
Effective tax rate	2.1%	10.0%	10.0%	10.0%	19.0%	19.0%	19.0%	19.0%	19.0%	19.0%	19.0%
After-tax cost of debt	7.8%	7.2%	7.2%	7.2%	6.5%	6.5%	6.5%	6.5%	6.5%	6.5%	6.5%
Weight of debt	67.7%	46.8%	33.0%	22.3%	7.1%	-7.3%	-17.6%	-28.5%	-37.7%	-44.5%	-44.5%
Weight of equity	32.3%	53.2%	67.0%	77.7%	92.9%	107.3%	117.6%	128.5%	137.7%	144.5%	144.5%
WACC	8.9%	9.2%	9.7%	10.2%	10.7%	11.3%	11.8%	12.3%	12.7%	13.0%	13.0%
Discount fact	0.92	0.84	0.77	0.70	0.63	0.56	0.51	0.45	0.40	0.35	0.31
PV of FCF	-16.9	-15.2	-12.4	9.6	17.5	23.3	23.0	19.1	16.4	18.3	16.2
Sum of FCF PV's	82.7										
FCF terminal growth rate	2.0%										
Terminal value	480.4										
PV of terminal value	150.1										
Unwind of discount	7.6										
Enterprise value	240.5										
Net debt 2024	127.7										
Employees liabilities	-1.3										
Dividend paid out in 2025 (ytd terms)	0.0										
Per share value (PLN)	14.86										

Source: Company, IPOPEMA Research

Figure 3. DDM Valuation

PLNm	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	Terminal Year
Dividends	0.0	0.0	0.0	0.0	0.0	0.0	15.5	16.3	15.6	21.8	21.8
Discount rate	11.0%	11.0%	11.0%	11.0%	11.0%	11.0%	11.0%	11.0%	11.0%	11.0%	11.0%
Discount factor	0.90	0.81	0.73	0.66	0.59	0.53	0.48	0.43	0.39	0.35	0.32
Discounted dividend	0.0	0.0	0.0	0.0	0.0	0.0	7.5	7.1	6.1	7.7	6.9
Sum of DD PV's	28.3										
DIV terminal growth rate	2.0%										
Terminal value	246.6										
PV of terminal value	78.2										
Discount unwind	7.5										
Equity value	114.1										
Per share value (PLN)	15.21										

Source: Company, IPOPEMA Research

Figure 4. Valuation summary

PLN	
DCF	14.86
DDM	15.21
Average	15.03

Source: Company, IPOPEMA Research

Relative valuation

As many of the company's international competitors are private, non-listed companies, and Polish companies operating on the PV market are either incomparable to ML System or there are not enough consensus readings, we decided to show ML System in comparison to international PV utility scale farm operators. This comparison is also imperfect.

Compared to the international peers' median of 2025E EV/EBITDA of 11.1x, ML System trades at 12.9x, which constitutes a 16.6% premium. In our opinion, such a high premium is not justified.

Figure 5. Relative Valuation

PRICE	Ticker	NAME	P/E			EV/EBITDA		
(LCU)			2025	2026	2027	2025	2026	2027
10.9	CSIQ.O	CANADIAN SOLAR	NULL	5.4	3.1	11.7	7.3	7.0
350.0	TSLA.O	TESLA	196.9	132.6	95.3	78.6	57.5	47.4
178.5	FSLR.O	FIRST SOLAR	12.0	8.1	6.5	8.6	6.0	4.9
765.0	6753.T	SHARP CORPORATION	28.5	10.1	11.2	10.5	10.9	8.6
13.9	688599.SS	TRINA SOLAR	NULL	18.9	13.6	19.4	10.5	5.6
4,289.0	5201.T	AGC INC.	11.2	9.3	7.1	5.0	4.5	4.0
1,789.0	6971.T	KYOCERA	98.4	29.1	21.9	16.7	12.2	10.7
1.9	SPWR.O	SUNPOWER CORPORATION	NULL	21.6	5.2	NULL	11.1	NULL
33.3	WBSV.VI	WIENERBERGER	13.2	10.9	9.9	6.7	6.0	5.5
		MEDIAN	20.9	10.9	9.9	11.1	10.5	6.3
17.2	MLSP.WA	ML SYSTEM	-9.6	-9.1	-29.0	12.9	8.9	5.3
		Premium/discount to median						
		ML SYSTEM	NaN	NaN	NaN	16.6%	-15.2%	-15.6%
		Our valuation						
		ML SYSTEM	-8.25	-7.89	-25.01	12.20	8.30	4.94
		Premium/discount to median						
		ML SYSTEM	NaN	NaN	NaN	10.0%	-20.8%	-21.9%

Source: Reuters, IPOPEMA Research

Changes in forecast

Figure 6. Changes in forecast

	2025			2026			2027		
	OLD	NEW	change	OLD	NEW	change	OLD	NEW	change
Revenues	186.1	174.7	-6.1%	241.4	265.2	9.9%	343.6	364.4	6.1%
EBITDA	39.9	23.9	-40.2%	48.0	30.1	-37.2%	62.4	44.0	-29.4%
Net profit	-3.8	-13.3	na	-1.3	-13.9	na	7.0	-4.4	na

Source: Company, IPOPEMA Research

4Q24 results overview

The company reported 4Q24 results in line with preliminary print. Still there are worrying clauses in the financial statements regarding going concern of the company:

- Gross debt amounts to PLN 133m as of end of 4Q24.
- The Management Board assessed that the assumption of the Group continuing as a going concern adopted for the preparation of these consolidated financial statements is justified. The Management Board is aware of the existence of significant uncertainties regarding events or circumstances that may raise serious doubts as to the Group's ability to continue its operations, the Group discloses the existence of such uncertainties.
- Considering the need for a significant reduction in employment, in order to reduce the competence gap, the organizational restructuring program has been spread over several months. As a result of the actions taken, the reduction of fixed costs should bring nearly PLN 15 million in savings in 2025 compared to the costs incurred in 2024.
- As of the date of preparation of this report, the value of contracts signed by the Group amounts to PLN 230.5 million, and the value of offers submitted by the Group with the probability of their implementation assessed by the Management Boards of the Group Companies at over 50% amounts to PLN 115.2 million.
- The process of selling the production hall put into use in 2024 is underway on a sale & lease back basis, which will allow for obtaining significant funds to increase working capital and repay part of the liabilities, while maintaining the assets necessary to implement the adopted strategy. It is planned to conclude a preliminary agreement by the end of May 2025.
- Actions are being taken to obtain "bridge" financing in an amount sufficient to continue the Group's operating activities until the funds from the transaction described in point 1 above are obtained. The parent company is analyzing and negotiating the offers of debt funds received in this regard. The process is planned to be finalized in May 2025.
- Financing for payment guarantees and contract guarantees secured by the State Treasury (KUKE S.A.) within the limit of approx. PLN 24 million and approx. EUR 2.2 million of export guarantees is being obtained. In the scope of payment guarantees, a combined structure of cooperation between BNP Paribas Bank Polska S.A. and KUKE S.A. is necessary. Due to the degree of advancement of the arrangements, the Management Board of the Company expects a decision from KUKE S.A. in the first days of May 2025, and then a decision from BNP Paribas Bank Polska S.A. approx. 2 to 3 weeks later.
- Work is underway to establish the terms of continued financing and repayment of receivables of financial creditors (BNP Paribas Bank Polska S.A., Bank Gospodarstwa Krajowego, Agencja Rozwoju Przemysłu S.A., Millennium Leasing Sp. z o.o. – hereinafter referred to as "Creditors") resulting from financing agreements concluded with Group companies.
- Work has been undertaken to agree on the terms of the cooperation agreement for the period of: (a) verification of the business plan submitted by the Company by an independent expert/financial advisor acting on behalf of the Creditors (such verified business plan will be used to agree on the target principles for repayment of the financial debt incurred by the Group Companies) and (b) negotiation by the Company of the terms of obtaining financing for working capital.

- In parallel, the Parent Company is taking steps to obtain foreign contracts covered by export guarantees, which will enable ensuring their financing by financial institutions.
- The Company assumes that under the cooperation agreement, the Creditors would undertake to refrain from actions aimed at collecting receivables, and the Bank Creditors would undertake, on agreed terms, to continue providing the Companies with working capital financing. The intention of the parties is to immediately sign a cooperation agreement, i.e. a standstill agreement creating a formal framework for the relations of the Companies and the Creditors during the transitional period needed to agree on the principles of further cooperation, implement remedial actions, ensuring the stabilization of the financing of the Parent Company and its subsidiaries. The negotiated terms of the cooperation agreement provide that the initial period of validity of this agreement will end on May 31, 2025, with the possibility of the Creditors expressing their consent to extend the period of its validity, and the Parent Company assumes that the period of such extension will generally not exceed 12 months.
- The Company has submitted applications to the Mazovian Tax Office and the Social Insurance Institution for deferral of the payment deadlines of public law liabilities. The submitted applications assume the postponement of the payment deadlines for public law arrears until July 2025, i.e. until the funds are obtained.

Figure 7. ML System: 4Q24A results overview (PLN m)

	1Q23	2Q23	3Q23	4Q23A	1Q24A	2Q24A	3Q24A	4Q24A	Y/Y	Q/Q	4Q24Aprel.	diff.
Revenues	46.09	48.42	39.72	59.03	40.12	31.27	42.33	48.56	-17.7%	14.7%	48.57	0.0%
Gross profit	4.25	4.08	10.01	13.57	7.70	3.33	-7.43	11.23	-17.3%	na	11.19	0.3%
EBITDA	7.44	-0.21	6.38	12.08	13.34	1.24	-11.11	-9.25	na	na	-8.97	3.1%
EBIT	0.14	-6.44	1.84	7.53	6.66	-5.95	-18.21	-14.93	na	na	na	na
Net profit	-2.26	-8.39	-0.10	6.11	5.87	-8.81	-21.62	-16.24	na	na	-16.24	na

Source: Company, IPOPEMA Research

1Q25 results preview

Figure 8. ML System: 1Q25 results preview (PLN m)

	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24	1Q25	Y/Y	Q/Q
Revenues	46.09	48.42	39.72	59.03	40.12	31.27	42.33	48.56	30.18	-24.8%	-37.8%
Gross profit	4.25	4.08	10.01	13.57	7.70	3.33	-7.43	11.23	-2.43	na	na
EBITDA	7.44	-0.21	6.38	12.08	13.34	1.24	-11.11	-9.25	-8.39	na	na
EBIT	0.14	-6.44	1.84	7.53	6.66	-5.95	-18.21	-14.93	-13.89	na	na
Net profit	-2.26	-8.39	-0.10	6.11	5.87	-8.81	-21.62	-16.23	-12.87	na	na

Source: Company, IPOPEMA Research

Risks to fair value

Demand volatility

ML System is exposed to the PV market, which in Poland and in Europe is undergoing a stagnation.

Unfavourable trend in prices of materials and services

The company is negotiating the standstill agreement with creditors. In case ML System fails to receive long term agreement it may lose liquidity quickly.

Unfavourable trend in prices of materials and services

Adverse trends such as rising raw material costs and inflation in transport service costs may hamper the company's profitability.

Potential rise in competition

Given the company's superior profitability, arising from complex solutions and a growing scale of operations, several local competitors might attempt to copy ML System's business model, which could potentially increase competition in the company's most important segments. ML System has, however, patented its technology which limits the possibilities of entering the most attractive segments of quantum dot PV modules. The regular PV modules are exposed to high competition as the market is fragmented and exposed to heavy imports, especially from China.

Workforce shortages

A shortage of skilled labour in the construction industry could result in ML System having insufficient employees to operate its business. There are no shortages at the moment, which would likely allow the company to lower its cost base and cost of third parties in quarters ahead.

Rise in receivables

The biggest threat to ML System would be a rapid increase in receivables stemming from construction contracts, which would cast a shadow over the profitability of the executed contracts.

Economy slowdown

Estimates for the Polish economy point to lower growth rates going forward. As a result, some investments could be suspended, which would raise questions about the level of ML System's future backlog. Decreasing EU funds are likely to accentuate the problem.

Breach of debt covenants

We do not assume in our model banks demanding rapid repayment of debt despite breached covenants. This however is likely to be achieved through the negotiations which in extreme scenario might turn sour for the company.

Financials

Figure 9. INCOME STATEMENT (PLN m)

	2020	2021	2022	2023	2024	2025E	2026E	2027E
Sales	127.3	188.8	281.7	189.3	162.3	174.7	265.2	364.4
Cost of goods & products sold	-96.6	-162.2	-244.6	-169.5	-147.5	-130.4	-196.4	-250.1
Gross profit	30.7	26.6	37.0	19.8	14.8	44.3	68.8	114.3
SG&A	-23.0	-30.0	-30.6	-35.1	-49.5	-53.2	-80.9	-111.1
Other operating activity	3.8	7.8	0.7	6.2	2.2	1.3	3.6	-3.3
EBIT	11.5	4.4	7.1	-9.1	-32.4	-7.6	-8.4	-0.1
Net financial activity	-1.3	-1.2	-6.2	-5.7	-9.2	-7.2	-7.0	-4.8
Pre-tax profit	10.3	3.2	0.9	-14.7	-41.7	-14.8	-15.4	-4.9
Tax	-0.1	-1.4	-0.7	-0.6	0.9	1.5	1.5	0.5
Minorities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	10.2	1.7	0.2	-15.4	-40.8	-13.3	-13.9	-4.4
EBITDA	22.1	24.4	36.5	18.2	-5.5	23.9	30.1	44.0

Source: Company, IPOPEMA Research

Figure 10. BALANCE SHEET (PLN m)

	2020	2021	2022	2023	2024	2025E	2026E	2027E
Long-term assets	184.8	247.9	256.4	433.1	414.9	429.7	432.5	435.6
Tangible assets	168.5	213.5	217.5	384.1	350.7	364.3	366.1	368.2
Receivables and loans	0.5	0.8	0.8	1.0	1.2	1.3	2.0	2.7
Intangible assets	11.0	11.8	17.0	25.1	30.5	31.5	31.6	31.6
Others	4.8	21.8	21.2	22.9	32.5	32.6	32.8	33.1
Current assets	118.8	142.3	174.8	145.6	81.5	83.0	124.9	167.4
Inventories	38.3	57.7	66.5	44.1	28.4	25.0	37.7	48.0
Receivables from construction activities	18.9	17.3	11.1	8.9	5.4	9.6	14.5	20.0
Trade receivables	40.3	41.7	69.0	71.4	40.3	38.3	58.1	79.9
Other	21.3	25.6	28.2	21.2	7.3	10.1	14.6	19.6
Total assets	303.5	390.2	431.2	578.7	496.4	512.7	557.4	603.0
Equity	144.4	146.2	146.4	197.9	146.5	133.2	119.3	115.0
Long-term liabilities	95.3	146.9	133.8	228.8	213.6	195.7	267.6	326.6
Interest bearing	25.5	43.4	35.6	63.4	53.7	53.7	53.7	53.7
Leasing	2.2	13.3	11.1	10.2	15.9	14.1	21.2	27.0
Deferred liabilities	61.4	85.9	82.7	149.9	141.2	124.9	188.1	239.6
Others	6.2	4.3	4.4	5.5	2.8	3.0	4.6	6.3
Short-term liabilities	63.9	97.1	151.0	151.9	136.3	183.8	170.6	161.5
Interest bearing	29.8	33.1	68.7	71.6	61.2	118.8	73.5	37.3
Trade liabilities	25.2	47.3	65.3	70.5	67.9	57.2	86.1	109.6
Deferred liabilities	6.4	8.7	10.4	0.0	0.0	0.0	0.0	0.0
Leasing	1.1	3.3	3.3	3.7	3.0	3.5	5.3	7.3
Others	1.4	4.6	3.3	6.2	4.3	4.3	5.8	7.2
Total liabilities& equity	303.5	390.2	431.2	578.7	496.4	512.7	557.4	603.0

Source: Company, IPOPEMA Research

Figure 11. CASH FLOW STATEMENT (PLN m)

	2020	2021	2022	2023	2024	2025E	2026E	2027E
Net profit	10.2	1.7	0.2	-15.4	-40.8	-13.3	-13.9	-4.4
Depreciation	10.6	20.0	29.4	20.8	26.6	31.4	38.5	44.1
Change in net working capital	-44.4	-15.0	-24.9	-22.6	16.9	-9.4	-8.5	-13.9
Other items	1.7	3.5	5.6	23.3	34.9	-6.3	72.7	59.1
Operating cash flow	-21.9	10.2	10.3	6.2	37.6	2.4	88.8	84.8
Purchases of tangibles & intangibles	-53.2	-55.4	-45.9	-171.6	72.3	-31.3	-38.7	-44.4
Others	4.2	0.0	0.0	0.0	-82.4	0.0	0.0	0.0
Investing cash flow	-49.0	-55.4	-45.9	-171.6	-10.1	-31.3	-38.7	-44.4
Change in interest-bearing debt	9.4	23.0	27.8	31.8	-20.1	56.5	-36.4	-28.2
Dividends	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	66.9	26.4	10.0	127.3	-22.1	-24.8	-9.3	-7.2
Financing cash flow	76.3	49.4	37.8	159.1	-42.2	31.6	-45.7	-35.5
Total cash flow	5.4	4.2	2.3	-6.3	-14.7	2.8	4.5	5.0
Cash at beginning of period	15.1	20.5	24.7	27.1	20.7	6.0	8.7	13.3
Cash at end of period	20.5	24.7	27.1	20.7	6.0	8.7	13.3	18.2

Source: Company, IPOPEMA Research

This document has been prepared by IPOPEMA Securities S.A. with its registered seat in Warsaw, Prózna 9, 00-107 Warsaw, Poland, entered into the Register of Entrepreneurs of the National Court Register maintained by the District Court for the City of Warsaw, XII Commercial Division of the National Court Register under entry number KRS 0000230737, the initial capital and paid capital in the amount of PLN 2.993.783,60, NIP 5272468122, www.ipopema.pl. IPOPEMA Securities S.A. is supervised by the Polish Financial Supervision Authority (Komisja Nadzoru Finansowego), Piękna 20, 00-549 Warsaw, Poland.

This document was prepared by IPOPEMA Securities S.A. for information purposes only. This document is addressed to IPOPEMA Securities S.A. clients entitled to receive it on the basis of contracts for the provision of services. This document, using mass media distribution channels, may also reach other investors. It has been produced independently of the company mentioned in this document and any forecasts, opinions and expectations are entirely those of IPOPEMA Securities S.A. Unless otherwise specified, the estimates and opinions contained in the document constitute an independent assessment of IPOPEMA Securities S.A. analysts preparing the document as of the date of issuing the document.

IPOPEMA Securities S.A. prepared this document with the preservation of all adequate diligence, thoroughness and reliability on the basis of publicly available information which IPOPEMA Securities S.A. believes to be reliable. The sources of data are primarily: Bloomberg, Reuters, EPFR, Polska Agencja Prasowa, WSE, Główny Urząd Statystyczny, Narodowy Bank Polski, financial press, online financial and economic services. While due diligence has been taken by IPOPEMA Securities S.A. to ensure that the facts stated herein are accurate and that any forecasts, opinions and expectations contained herein are fair and reasonable, IPOPEMA Securities S.A. has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this document. The opinions expressed in the document can change without notice and IPOPEMA Securities S.A. is under no obligation to keep these opinion current. None of the IPOPEMA Securities S.A. or any other person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith provided that IPOPEMA Securities S.A. has been exercised due diligence and integrity during its preparation. This document may be sent to the mass media, however its copying or publishing in whole or in part as well as dissemination of information enclosed to it is allowed only with prior permission of IPOPEMA Securities S.A. This document nor any copy hereof is not to be distributed directly or indirectly in the United States, Australia, Canada, Serbia or Japan, subject to the following section.

Important disclosures for U.S. Persons: Auerbach Grayson & Company Inc. may distribute this document in the U.S. This document is provided for distribution to Major U.S. Institutional Investors in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended and may not be furnished to any other person in the U.S. Each Major U.S. Institutional Investor that receives this document shall not distribute or provide it to any other person. Under no circumstances should any U.S. recipient of this document effect any transaction to buy or sell securities or related financial instruments through IPOPEMA Securities S.A. Any U.S. recipient of this document wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this document should do so only through Auerbach Grayson & Company Inc. 25 West 45th Street, Floor 16, New York, NY 10036 U.S. which is a registered broker-dealer in the U.S. IPOPEMA Securities S.A. is not a registered broker-dealer in the U.S. and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. IPOPEMA Securities S.A. and its research analysts are not associated persons of Auerbach Grayson & Company, nor are they affiliated with Auerbach Grayson & Company. The author of this document whose name appears in this document is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"), is not subject to the SEC rules on research analysts and is not subject FINRA's rules on debt research analysts and debt research reports, equity research analysts and equity research reports. U.S. recipients should take into account that information on non-U.S. securities or related financial instruments discussed in this document may be limited. The financial instruments of non-U.S. issuers may not be registered with, or be subject to the regulations of, the SEC. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the U.S.

This document does not constitute any offer to sell or induce any offer to buy or sell any financial instruments, cannot be relied on in connection with any contract or liability and does not constitute advertising or promotion of a financial instrument or the company. Investment decisions should only be made on the basis of a prospectus or other publicly available information and materials.

The document was prepared without taking into account the needs and situation of the recipients of the document. When preparing the document, IPOPEMA Securities S.A. does not examine the recipient's investment objectives, risk tolerance level, time horizon and financial standing of the investors. The company or the financial instruments discussed in the document may not be suitable for the users of the document, i.e. it may not be suitable for the specific objectives and time horizon or the financial situation. Information included in the document cannot be regarded as a substitute for obtaining investment advice service. The value of financial instruments may fluctuate, including declines. Changes in FX rates may have an adverse effect on the value of investments. The investment in financial instruments is linked to investment risks including loss of entire or part of the invested capital. Past performance is not necessarily indicative of future results. IPOPEMA Securities S.A. points out that the price of financial instruments is affected by many different factors that are or may be independent of the company and the results of its operations. These include, among others changing economic, legal, political and tax conditions. IPOPEMA Securities S.A. may have issued in the past or may issue other documents in the future, presenting other conclusions, not consistent with those presented herein document. Such documents reflect different assumptions, points of view and analytical methods adopted by the analysts preparing them.

Investors should be aware that IPOPEMA Securities S.A. or its related entities may have a conflict of interest that could affect this document's objectivity. The investor should assume that IPOPEMA Securities S.A. or its related entities may provide services in favour of the company and obtain remuneration on this account. They may also have another financial interest with respect to the company. IPOPEMA Securities S.A. or its related entities may seek to do business with the company or other entities mentioned in this document. IPOPEMA Securities S.A. has an organizational structure and internal regulations in place to ensure that the client's interests are not compromised in the event of a conflict of interests, in relation to preparing this document. Conflict of interest management policy is available on the website at <https://www.ipopemasecurities.pl/analizy-i-rekomendacje,p162>. This document was prepared irrespective and independently of the interests of IPOPEMA Securities S.A., the company that is the subject of this document and holder of financial instrument issued by aforementioned company. IPOPEMA Securities S.A., its shareholders, employees and associates may hold long or short positions in the company's financial instruments or other financial instruments related to the company's financial instruments.

On the order of the Warsaw Stock Exchange S.A. ("WSE"), IPOPEMA Securities S.A. creates analytical materials for the following companies: ATM Grupa S.A., Mirbud S.A., ML System S.A., OncoArendi Therapeutics S.A., PointPack S.A., SFD S.A., Synektik S.A., Fabryka Farb i Lakierów Śnieżka S.A., Ultimate Games S.A., Vigo System S.A. The WSE has proprietary copyrights to these materials. For the preparation of IPOPEMA Securities S.A. receives remuneration from the WSE. Information on the program is available on the website <https://www.gpw.pl/gpwpa>.

On the order of the Bursa de Valori Bucuresti S.A. ("BVB"), IPOPEMA Securities S.A. creates analytical materials for the following companies: Bittnet Systems S.A. and Impact Developer & Contractor S.A. The BVB has proprietary copyrights to these materials. For the preparation of IPOPEMA Securities S.A. receives remuneration from the BVB.

IPOPEMA Securities S.A. uses a number of valuation methodologies including discounted cash flows models (such as discounted operating earnings or dividend discount model), and earnings and cash-flow based models, which are often related to comparisons with selected peer companies. Cash flow models encapsulate the cash streams forecast to flow to a company, and are widely used in the investment industry. Peer comparisons factor in amongst other factors, differential growth rates, and indicate how expensive one company might appear relative to a chosen comparator. The subjective opinions of the report's author or authors, formed by their knowledge and experience, play a significant role in the valuation. Also included are assumptions on numerous economic variables, particularly interest rates, inflation and exchange rates and varying these assumptions could results in significantly different opinions. The strength of the earnings and cash flow based models is the closer attention to a company on a standalone basis, and tying the valuation to its fundamental value. The weakness of such method is the number of assumptions, which need to be adopted and resulting sensitivity to those assumptions. The peer comparisons methods are less dependent on the analyst's judgment as to the individual parameters, however the problem with this method appears when the peer comparator is over- or undervalued. Moreover, leading multiples (based on the future earnings, book values, operating profit or cash flows) include an analyst's estimate of those values.

This document was not transferred to the company prior to its publication. This document was prepared according to the author's own view, assumptions and knowledge.

Recommendations issued by IPOPEMA Securities S.A. they are valid for a period of 12 months from the date of issue, unless they are updated during this period. IPOPEMA Securities S.A. updates the issued recommendations depending on the market situation and subjective analysts' assessment.

This document is an investment research within the meaning of Art. 36 par. 1 of the Commission Delegated Regulation (EU) 2017/565.

List of all recommendations regarding any financial instrument or issuer that have been disseminated within the last 12 months by IPOPEMA Securities S.A. is available on the website at <https://www.ipopemasecurities.pl/analizy-i-rekomendacje,p162>.

The date and the time stated on the front page is the date of the preparation of this document. The price used throughout the recommendation to calculate adequate ratios is the "last" price stated on the front page of this document.

The definitions of terms used in the document include:

NII – Net interest income – interest income minus interest expense.

Net F&C – Net fee and commission income – fee and commission income minus fee and commission expense.

LLP – loan loss provisions – an expense set aside as an allowance for bad loans.

NPL – non-performing loan – loans that are in default or close to be in default.

Cost/Income – operating expenses divided by total banking revenue.

ROE – return on equity – net income (or adjusted net income) divided by the average shareholders' equity.

ROA – return on assets – net income (or adjusted net income) divided by the average assets.

EBIT – earnings before interests and tax.

EBITDA – earnings before interests, tax, depreciation and amortization.

EPS – earnings per share – the net income (or adjusted net income) divided by the number of shares outstanding.

P/E – price to earnings ratio – price divided by earnings per share.

PEG – P/E ratio divided by the annual EPS growth, usually over a certain period of time.

CAGR – compound annual growth rate.

BVPS – book value per share, the book value of the Company's equity divided by the number of shares outstanding.

P/BV – price to book value - price divided by the BVPS.

DPS – dividend per share – dividend of a given year divided by the number of shares outstanding.

DY – dividend yield – dividend of a given year divided by the current price.

DDM – dividend discount model – a fundamental method of valuation based on the assumption that the value of stock equals the sum of all discounted future dividends.

FV – Fair Value, calculated based on valuation methods outlined in the document.

The author of this document has no conflict of interest with the company that is the subject of this document. The point of view expressed in the document reflects the personal opinion of the author of the document on the analyzed company and its financial instruments. Investors should be aware that flexible part of the author's compensation may depend on general financial performance of IPOPEMA Securities S.A.

IPOPEMA Securities S.A. shall act with due diligence, honestly, fairly, professionally and in accordance with the provisions of the applicable law.

IPOPEMA Securities S.A. does not guarantee achieving the investor's investment objective, the performance of company or prospective prices referred to herein.

When applying ratings for companies following criteria are used with regards to the difference between IPOPEMA's FV and company's price at the date of recommendation:

Rating	Difference between FV and price at recommendation
Buy	Above 10%
Hold	In between (and including) -10% and 10%
Sell	Below -10%

IPOPEMA Research - Distribution by rating category (1 January – 31 March 2025)

	Number	%
Buy	13	81%
Hold	1	6%
Sell	2	13%
Total	16	100%

Rating History – ML System

Date	Recommendation	Fair Value	Price at recommendation	Author
09/09/2021	BUY	PLN 127.00	PLN 108.40	Robert Maj
06/05/2022	BUY	PLN 90.94	PLN 73.50	Robert Maj
26/08/2022	BUY	PLN 104.48	PLN 75.75	Robert Maj
21/11/2022	BUY	PLN 83.18	PLN 50.60	Robert Maj
05/04/2023	BUY	PLN 92.22	PLN 62.50	Robert Maj
02/10/2023	BUY	PLN 87.29	PLN 65.30	Robert Maj
24/04/2024	BUY	PLN 58.45	PLN 47.20	Robert Maj
10/10/2024	SELL	PLN 31.54	PLN 36.80	Robert Maj
20.05.2025	SELL	PLN 15.03	PLN 17.22	Robert Maj